Business Card for Marlo Searcy:


Principal Clinical Coding Specialist
South San Francisco, CA area
Email Avail: 3 Day Free Trial


1 Dna Way
South San Francisco, CA 94080

Tel: (650) 225-1000

Last updated on 2018-01-15


About Marlo Searcy:

Marlo Searcy works as an Principal Clinical Coding Specialist for Genentech, Inc. at South San Francisco, CA. The company's webpage is http://www.gene.com. For email, phone number and executive profiles for Principal Clinical Coding Specialist and other executives of Genentech, Inc. at South San Francisco, CA, check Genentech, Inc. at Joesdata.com. Not the Marlo Searcy you are looking for? Do a quick search in our website and find other people named Marlo Searcy.
Marlo Searcy's Work History:
No information available..

Marlo Searcy's Education:
No information available..

Marlo Searcy's Co-workers:
As of January 26, 2021, Marlo Searcy has 1358 co-workers under the company name Genentech, Inc. at Joesdata.com.

About Genentech, Inc.:

Genentech, Inc. is located at 1 Dna Way , South San Francisco, CA 94080. It has over 10K employees. Its revenue is over $1B.

Company News:
2018-09-13 19:18:41
FDA Approves Subcutaneous Formulation of Actemra for Use in Active Systemic Juvenile Idiopathic Arthritis (SJIA), a Rare Form of Juvenile Arthritis
2018-09-13 17:30:39
FDA Approves Subcutaneous Formulation of Actemra for Use in Active Systemic Juvenile Idiopathic Arthritis (SJIA), a Rare Form of Juvenile Arthritis
2018-09-06 19:24:23
Genentech to Present New Data from Its Extensive Lung Cancer Program at the 2018 World Conference on Lung Cancer (WCLC)
2018-08-30 17:30:48
Positive Phase III Results for Genentechs HEMLIBRA (emicizumab-kxwh) for Hemophilia A Without Factor VIII Inhibitors Published in New England Journal of Medicine
2018-08-13 19:19:15
FDA Grants Breakthrough Therapy Designation for Xolair (Omalizumab) for Food Allergies
2018-08-13 17:30:37
FDA Grants Breakthrough Therapy Designation for Xolair (Omalizumab) for Food Allergies
2018-07-25 17:42:26
Genentech Unveils Positive Phase II Results for the First-Ever Eye Implant to Achieve Sustained Delivery of a Biologic Medicine to Treat People With Wet Age-Related Macular Degeneration (AMD)
2018-07-25 17:31:17
Genentech Unveils Positive Phase II Results for the First-Ever Eye Implant to Achieve Sustained Delivery of a Biologic Medicine to Treat People With Wet Age-Related Macular Degeneration (AMD)
2018-07-20 18:54:47
Genentech to Present New Data Demonstrating the Breadth and Depth of Its Alzheimers Program at the Upcoming Alzheimer's Association International Conference (AAIC)
2018-07-20 17:30:51
Genentech to Present New Data Demonstrating the Breadth and Depth of Its Alzheimers Program at the Upcoming Alzheimer's Association International Conference (AAIC)

People in the same industry: